EDIT Editas Medicine, Inc. Stock Quote

publish chart | save to portfolio | create alert

Settings

EDIT [NASD]

Editas Medicine, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.72	Insider Own	0.10%	Shs Outstand	62.14M	Perf Week	8.76%
Market Cap	1.87B	Forward P/E	-	EPS next Y	-3.32	Insider Trans	-32.69%	Shs Float	61.48M	Perf Month	3.10%
Income	-91.20M	PEG	-	EPS next Q	-0.75	Inst Own	82.80%	Short Float	18.31%	Perf Quarter	-8.94%
Sales	91.60M	P/S	20.40	EPS this Y	-14.60%	Inst Trans	1.93%	Short Ratio	12.62	Perf Half Y	16.17%
Book/sh	7.10	P/B	4.49	EPS next Y	-94.20%	ROA	-16.40%	Target Price	38.00	Perf Year	6.69%
Cash/sh	8.46	P/C	3.77	EPS next 5Y	-	ROE	-26.70%	52W Range	14.01 - 39.96	Perf YTD	7.73%
Dividend	-	P/FCF	-	EPS past 5Y	-46.80%	ROI	-53.70%	52W High	-20.17%	Beta	1.78
Dividend %	-	Quick Ratio	9.20	Sales past 5Y	-	Gross Margin	-	52W Low	127.69%	ATR	1.79
Employees	208	Current Ratio	9.20	Sales Q/Q	1533.10%	Oper. Margin	-	RSI (14)	59.65	Volatility	5.65% 6.29%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	118.90%	Profit Margin	-99.60%	Rel Volume	2.05	Prev Close	30.59
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	Payout	-	Avg Volume	891.45K	Price	31.90
Recom	2.70	SMA20	8.10%	SMA50	4.63%	SMA200	12.34%	Volume	1,830,636	Change	4.28%

Nov-03-20

Initiated

Robert W. Baird

Underperform

$14

Jun-18-20

Resumed

SunTrust

Buy

$45

Feb-21-20

Initiated

Wells Fargo

Equal Weight

$28

Apr-12-19

Initiated

Evercore ISI

Outperform

Oct-10-18

Initiated

Guggenheim

Neutral

Sep-21-18

Initiated

Raymond James

Outperform

$40

May-15-18

Reiterated

Chardan Capital Markets

Buy

$72.50 → $55

Feb-13-18

Initiated

CLSA

Underperform

Jan-23-18

Upgrade

SunTrust

Hold → Buy

Jul-14-17

Initiated

SunTrust

Hold

$17

Mar-28-17

Initiated

Chardan Capital Markets

Buy

$65

Aug-10-16

Upgrade

Jefferies

Hold → Buy

Jun-02-16

Initiated

Jefferies

Hold

Feb-29-16

Initiated

Morgan Stanley

Equal-Weight

$28

Feb-29-16

Initiated

JP Morgan

Neutral

Feb-29-16

Initiated

JMP Securities

Mkt Outperform

Nov-10-20 04:01PM	Editas Medicine Reports Inducement Grants to New Chief Medical Officer GlobeNewswire
05:41AM	Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Just Slashed Next Year's Revenue Estimates By 20% Simply Wall St.
Nov-09-20 04:05PM	Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit GlobeNewswire
09:00AM	Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer GlobeNewswire
Nov-07-20 09:06AM	Editas Medicine, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates Simply Wall St.
Nov-06-20 03:30PM	Editas Medicine, Inc. (EDIT) Q3 2020 Earnings Call Transcript Motley Fool
11:24AM	Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus Zacks
Nov-05-20 05:25PM	Editas Medicine (EDIT) Tops Q3 Earnings and Revenue Estimates Zacks
04:15PM	Editas Medicine, Inc. to Host Earnings Call ACCESSWIRE
04:02PM	Editas Medicine Announces Third Quarter 2020 Results and Update GlobeNewswire
Nov-02-20 10:31AM	Understanding Editas Medicine's Unusual Options Activity Benzinga
Oct-29-20 04:01PM	Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update GlobeNewswire
Oct-21-20 10:23AM	Understanding Editas Medicine's Unusual Options Activity Benzinga -8.77%
Oct-13-20 09:45AM	The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher Zacks
Oct-12-20 09:45AM	Booming Gene Editing Market to Pep Up These 5 Biotech Stocks Zacks
Oct-10-20 09:55AM	A Look At The Fair Value Of Editas Medicine, Inc. (NASDAQ:EDIT) Simply Wall St.
Oct-07-20 10:04AM	Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other Stocks Barrons.com +7.93%
Oct-06-20 07:45PM	Hedge Funds Have Never Been This Bullish On Editas Medicine, Inc. (EDIT) Insider Monkey
Sep-30-20 06:45AM	Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool
Sep-18-20 06:43PM	Why You Must Re-evaluate Your Portfolio Now Motley Fool
Sep-11-20 07:00AM	Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference GlobeNewswire
Sep-05-20 11:32AM	Why Is Editas (EDIT) Down 17.3% Since Last Earnings Report? Zacks
Sep-04-20 08:00AM	Editas Medicine to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-26-20 11:54AM	If You Had Bought Editas Medicine (NASDAQ:EDIT) Stock Three Years Ago, You Could Pocket A 65% Gain Today Simply Wall St.
Aug-25-20 11:54AM	Editas' SCD Candidate Gets FDA's Rare Pediatric Disease Tag Zacks
03:02AM	Editas Scores Rare Disease Tag For EDIT-301 Sickle Cell Treatment SmarterAnalyst
Aug-24-20 08:30AM	Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease GlobeNewswire -5.13%
Aug-10-20 11:54AM	Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y Zacks
Aug-06-20 04:05PM	Editas Medicine Announces Second Quarter 2020 Results and Update GlobeNewswire +13.39%
04:01PM	Editas Medicine Regains Full Global Rights to Ocular Medicines GlobeNewswire
Jul-30-20 12:33PM	Earnings Preview: Editas Medicine (EDIT) Q2 Earnings Expected to Decline Zacks
Jul-29-20 08:00AM	Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline GlobeNewswire
Jul-27-20 04:01PM	Editas Medicine Appoints Gad Berdugo as Chief Business Officer GlobeNewswire +6.09%
Jul-25-20 11:52AM	Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases. Barrons.com
07:03AM	Could Editas Medicine Be a Millionaire-Maker Stock? Motley Fool
Jul-23-20 04:01PM	Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update GlobeNewswire
Jul-21-20 07:07AM	2 Best Gene-Editing Stocks to Buy in July Motley Fool -6.88%
Jul-12-20 08:45AM	What You Need To Know About Editas Medicine, Inc.'s (NASDAQ:EDIT) Investor Composition Simply Wall St.
Jul-09-20 07:31AM	3 Top Biotech Stocks to Watch in July Motley Fool
Jul-07-20 09:00AM	Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing GlobeNewswire
09:00AM	Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing PR Newswire
Jul-02-20 11:32AM	Better Buy: Editas Medicine vs. Intellia Motley Fool
Jun-27-20 10:20PM	Do Hedge Funds Love Editas Medicine, Inc. (EDIT)? Insider Monkey
Jun-26-20 04:05PM	Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares GlobeNewswire -7.93%
08:21AM	How gene therapy and CRISPR are helping to cure blindness MarketWatch
Jun-24-20 05:12AM	Editas Medicine Falling 6% In Pre-Market On Offer Pricing SmarterAnalyst -10.51%
Jun-23-20 09:48PM	Editas Medicine Announces Pricing of Offering of Common Stock GlobeNewswire
04:21PM	Editas Medicine Announces Offering of Common Stock GlobeNewswire
Jun-19-20 08:41AM	Editas (EDIT) in Focus: Stock Moves 8.6% Higher Zacks
Jun-12-20 06:00AM	Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease GlobeNewswire +7.92%
Jun-06-20 11:31AM	Editas (EDIT) Up 10.6% Since Last Earnings Report: Can It Continue? Zacks
Jun-04-20 08:13AM	Edited Transcript of EDIT earnings conference call or presentation 7-May-20 12:00pm GMT Thomson Reuters StreetEvents
Jun-03-20 07:02AM	Why Editas Medicine Is Now the CRISPR Stock to Really Watch Motley Fool
May-29-20 12:00PM	Editas (EDIT) Moves to Buy: Rationale Behind the Upgrade Zacks
May-23-20 07:28AM	4 Promising Stocks to Own That You Probably Forgot About Motley Fool
May-22-20 07:39AM	Here's Why Editas Could Beat Intellia to a CRISPR Therapy Motley Fool
May-18-20 06:21PM	Beam Therapeutics Taking Novel Approach to Gene Therapy GuruFocus.com
May-15-20 09:20AM	Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies GlobeNewswire +8.01%
May-10-20 09:28AM	Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
May-08-20 12:38PM	Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y Zacks
07:30AM	Editas Medicine, Inc. (EDIT) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 10:15AM	Editas Medicine (EDIT) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM	Editas Medicine Announces First Quarter 2020 Results and Update GlobeNewswire
May-04-20 08:25AM	Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth Simply Wall St. +12.34%
Apr-30-20 08:05AM	Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update GlobeNewswire
Apr-29-20 09:00AM	Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers GlobeNewswire
Apr-28-20 12:33PM	Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-06-20 08:59AM	Are Options Traders Betting on a Big Move in Editas Medicine (EDIT) Stock? Zacks +9.15%
Mar-27-20 11:31AM	Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue? Zacks
Mar-19-20 10:40AM	Editas Medicine (EDIT) Catches Eye: Stock Jumps 9% Zacks +9.35%
Mar-11-20 09:20PM	Edited Transcript of EDIT earnings conference call or presentation 26-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -6.63%
Mar-05-20 08:29AM	Editas, Allergan Start Dosing in Early-Stage Eye Disease Study Zacks +9.30%
Mar-04-20 05:00AM	Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 GlobeNewswire
Feb-28-20 09:06AM	Editas Medicine, Inc. Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? Simply Wall St. +5.72%
Feb-27-20 02:56PM	Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates Zacks -6.38%
Feb-26-20 05:25PM	Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:02PM	Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update GlobeNewswire
Feb-19-20 04:02PM	Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update GlobeNewswire
Feb-17-20 07:12AM	How Many Editas Medicine, Inc. (NASDAQ:EDIT) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Feb-06-20 12:30PM	Shares of gene-editing startup Beam jump 40% after upsized IPO American City Business Journals
Feb-03-20 11:27AM	Andreas Halvorsen Trims Adaptive Biotechnologies Stake GuruFocus.com
Jan-17-20 02:09PM	European ruling threatens Broad's CRISPR gene-editing patents American City Business Journals
Jan-13-20 09:00AM	Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference GlobeNewswire
08:55AM	Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer GlobeNewswire
Jan-10-20 04:30PM	Editas Medicine Reports Inducement Grants to New Chief Financial Officer GlobeNewswire
05:59AM	Implied Volatility Surging for Editas (EDIT) Stock Options Zacks
Jan-09-20 09:00AM	Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth GlobeNewswire
Jan-06-20 11:00PM	Crispr puts first human in-body gene editing to test Financial Times
09:45AM	Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
Jan-02-20 09:00AM	Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-30-19 04:07PM	Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison Investor's Business Daily
03:40PM	Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial Yahoo Finance Video
Dec-24-19 12:00PM	Editas Medicine (EDIT) Is Up 6.66% in One Week: What You Should Know Zacks
Dec-19-19 09:15AM	Editas Medicine (NASDAQ:EDIT) Shareholders Booked A 90% Gain In The Last Three Years Simply Wall St.
Dec-14-19 08:42PM	Did Hedge Funds Drop The Ball On Editas Medicine, Inc. (EDIT) ? Insider Monkey
Dec-12-19 11:30AM	Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report? Zacks
Dec-09-19 06:00PM	Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
Dec-03-19 01:03AM	Don't Judge a Month by its First Day Zacks
Dec-02-19 11:43AM	Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-20-19 09:41AM	Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher Zacks

Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Albright Charles	EVP/Chief Scientific Officer	Nov 09	Sale	31.21	228	7,116	24,907	Nov 10 04:13 PM
Albright Charles	EVP/Chief Scientific Officer	Oct 15	Sale	31.39	3,000	94,170	25,135	Oct 16 04:38 PM
Collins Cynthia	CEO	Aug 20	Sale	36.66	1,976	72,440	45,022	Aug 21 04:12 PM
Albright Charles	EVP/Chief Scientific Officer	Aug 17	Option Exercise	16.51	10,000	165,100	38,135	Aug 19 04:44 PM
Albright Charles	EVP/Chief Scientific Officer	Aug 17	Sale	35.29	10,000	352,900	28,135	Aug 19 04:44 PM
Albright Charles	EVP/Chief Scientific Officer	Aug 07	Sale	34.99	238	8,328	28,135	Aug 10 04:24 PM
Albright Charles	EVP/Chief Scientific Officer	Aug 06	Option Exercise	16.51	10,000	165,100	38,373	Aug 10 04:24 PM
Albright Charles	EVP/Chief Scientific Officer	Aug 06	Sale	37.47	10,000	374,700	28,373	Aug 10 04:24 PM
Albright Charles	EVP/Chief Scientific Officer	Jul 15	Sale	32.22	3,000	96,660	28,373	Jul 17 05:32 PM
Albright Charles	EVP/Chief Scientific Officer	May 06	Sale	25.28	151	3,817	31,373	May 08 04:17 PM
Albright Charles	Chief Scientific Officer	Feb 07	Sale	26.95	622	16,763	31,524	Feb 10 04:34 PM
Albright Charles	Chief Scientific Officer	Feb 03	Sale	26.54	5,549	147,288	20,553	Feb 04 05:24 PM
Albright Charles	Chief Scientific Officer	Jan 31	Option Exercise	0.00	17,977	0	26,102	Feb 04 05:24 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience